Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:8618
Name oral cavity cancer
Definition A gastrointestinal system cancer that is located_in the oral cavity.
Source DiseaseOntology.org
Alt Ids DOID:9049 DOID:9055 DOID:8617 DOID:0050627
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer oral cavity cancer

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
ABL1 G250R ABL1 G251D Nilotinib oral cavity cancer no benefit detail...
Unknown unknown Duvelisib + unspecified PD-L1 antibody oral cavity cancer not applicable detail...
Unknown unknown Capmatinib oral cavity cancer not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01218048 Phase II Cisplatin Carboplatin Cetuximab ERBITUX; Followed by Adjuvant Treatment With Chemoradiation and ERBITUX; for Locally Advanced Head and Neck Squamous Cell Carcinoma Completed
NCT01316757 Phase II Carboplatin + Cetuximab + Erlotinib + Paclitaxel Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Completed
NCT01414426 Phase II Vandetanib Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions Unknown status
NCT01467115 Phase II Leucovorin Cisplatin + Docetaxel + Fluorouracil Filgrastim Cetuximab INDUCTION CHEMOTHERAPY FOLLOWED BY CETUXIMAB AND RADIATION THERAPY FOR HEAD AND NECK CANCER Completed
NCT01790204 Phase Ib/II Phenethyl isothiocyanate A Study of the Effects of PEITC on Oral Cells With Mutant p53 Completed
NCT02124850 Phase I Cetuximab A Phase Ib Study of Neoadjuvant Immune Biomarker Modulation With ERBITUX® (Cetuximab) and VTX-2337 Terminated
NCT02262741 Phase I Tremelimumab Durvalumab A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 With Tremelimumab or Tremelimumab Alone in Head and Neck Cancer Completed
NCT02449681 Phase II TH-4000 Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS Terminated
NCT02643550 Phase Ib/II Cetuximab + Monalizumab Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Recruiting
NCT02734537 Phase II Cisplatin Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery Recruiting
NCT02795156 Phase II Cabozantinib Afatinib Regorafenib Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations Recruiting
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting
NCT03040999 Phase III Cisplatin + Pembrolizumab Cisplatin Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412) Active, not recruiting
NCT03179956 Phase I Ribociclib Impact of Ribociclib on Head and Neck Squamous Cell Cancer Terminated
NCT03389477 Phase II Cisplatin + Palbociclib Cetuximab + Palbociclib Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma Recruiting
NCT03529422 Phase I Durvalumab + Tremelimumab Durvalumab and Tremelimumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN Recruiting
NCT03539198 Phase 0 Nivolumab Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer Recruiting
NCT03765918 Phase III Pembrolizumab Cisplatin + Pembrolizumab Cisplatin Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) Recruiting
NCT04080804 Phase II Nivolumab Nivolumab + Relatlimab Ipilimumab + Nivolumab Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer Recruiting
NCT04128696 Phase III Pembrolizumab GSK3359609 + Pembrolizumab Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (INDUCE-3) Recruiting
NCT04428151 Phase II Lenvatinib + Pembrolizumab Docetaxel Paclitaxel Capecitabine Cetuximab Lenvatinib Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) Recruiting
NCT04428333 Phase III Carboplatin + Fluorouracil + Pembrolizumab Cisplatin + Fluorouracil + GSK3359609 + Pembrolizumab Cisplatin + Fluorouracil + Pembrolizumab Carboplatin + Fluorouracil + GSK3359609 + Pembrolizumab Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Recruiting
NCT04471415 Phase Ib/II DRP-104 Atezolizumab + DRP-104 First-in-human Study of DRP-104 as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. Recruiting
NCT04477759 Phase I Atezolizumab Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer (DEHART) Not yet recruiting